Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | BCR | P11274 | 3/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658895 | 0.87 | HDAC1 (0.50) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL658401 | 0.84 | HDAC1 (0.66) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL658238 | 0.82 | HDAC6 (0.47) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL1919049 | 0.80 | HDAC1 (0.53) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL658194 | 0.77 | HDAC1 (0.47) | HDAC6HDAC1 | |
| SCHEMBL659119 | 0.74 | CDK2 (0.54) | HDAC6 | |
| SCHEMBL197796 | 0.74 | LMNA (0.49) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL658003 | 0.73 | HDAC1 (0.52) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL3348358 | 0.73 | CDK2 (0.52) | HDAC1 | |
| SCHEMBL657216 | 0.73 | CDK2 (0.37) | HDAC6HDAC1HDAC8HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | claimed |
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
| JP-2011529504-A | — | — | 2011-12-08 | — | — | JP | claimed |
| EP-2326622-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010014611-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-02-04 | — | — | WO | claimed |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC6 7/4885HDAC1 1/4885HDAC8 8/4885 |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC6 7/4885HDAC1 1/4885HDAC8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.